NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹61 Cr | ₹101 Cr | ₹135 Cr | ₹143 Cr | ₹118 Cr |
What is the latest Total Non-Current Liabilities ratio of NATCO PHARMA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹61 Cr |
Mar2023 | ₹101 Cr |
Mar2022 | ₹135 Cr |
Mar2021 | ₹143 Cr |
Mar2020 | ₹118 Cr |
How is Total Non-Current Liabilities of NATCO PHARMA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹61 Cr | -39.30 | |
Mar2023 | ₹101 Cr | -25.61 | |
Mar2022 | ₹135 Cr | -5.46 | |
Mar2021 | ₹143 Cr | 21.31 | |
Mar2020 | ₹118 Cr | - |
Compare Total Non-Current Liabilities of peers of NATCO PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATCO PHARMA | ₹15,070.4 Cr | -5.4% | 2.3% | -17.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹438,778.0 Cr | 2.3% | 5.6% | 21.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹161,949.0 Cr | 1.5% | 4.2% | 51.2% | Stock Analytics | |
CIPLA | ₹123,222.0 Cr | 0% | 2.9% | 10% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,205.0 Cr | 0.6% | 0.9% | 23.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹98,707.7 Cr | 0.8% | 1.8% | -5.4% | Stock Analytics |
NATCO PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATCO PHARMA | -5.4% |
2.3% |
-17.5% |
SENSEX | 0.9% |
4.2% |
8.3% |
You may also like the below Video Courses